Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Type 2 Diabetic Nephropathy Clinical Trial

Official title:
A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan

Status Completed

Clinical Trial Summary

This is a prospective, multi-center, randomized, open-label, parallel-arm controlled study, for which a total of 216 patients with type 2 diabetic nephropathy (Stage II-IV) will be enrolled. The subjects will be randomized to three groups in 1:1:1 ratio. One group receive Alfacalcidol 0.25ug/day and Irbesartan 150mg/day for 16 consecutive weeks. The second group receive Alfacalcidol 0.25ug/day alone for 16 consecutive weeks. The third group receive Irbesartan 150mg/day alone for 16 consecutive weeks. All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03147677
Study type	Interventional
Source	The Third Xiangya Hospital of Central South University
Contact
Status	Completed
Phase	Phase 4
Start date	July 28, 2016
Completion date	December 30, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06182891` - Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy	N/A
Terminated	`NCT01488877` - A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy	Phase 1
Active, not recruiting	`NCT01300273` - Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy	Phase 4